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Abstract 
 
Background: Several studies have described the clinical characteristics of patients with novel 
coronavirus (SARS-CoV-2) infected pneumonia (COVID-19), indicating severe patients tended to 
have higher neutrophil to lymphocyte ratio (NLR). Whether baseline NLR could be an independent 
predictor of in-hospital death in Chinese COVID-19 patients remains to be investigated. 
 
Methods: A cohort of patients with COVID-19 admitted to the Zhongnan Hospital of Wuhan 
University from January 1 to February 29 was retrospectively analyzed. The baseline data of 
laboratory examinations, including NLR, were collected. Univariate and multivariate logistic 
regression models were developed to assess the independent relationship between the baseline NLR 
and in-hospital all-cause death. A sensitivity analysis was performed by converting NLR from a 
continuous variable to a categorical variable according to tertile. Interaction and stratified analyses 
were conducted as well. 
 
Results: 245 COVID-19 patients were included in the final analyses, and the in-hospital mortality was 
13.47%. Multivariate analysis demonstrated that there was 8% higher risk of in-hospital mortality for 
each unit increase in NLR (Odds ratio [OR] = 1.08; 95% confidence interval [95% CI], 1.01 to 1.14; 
P = 0.0147). Compared with patients in the lowest tertile, the NLR of patients in the highest tertile had 
a 15.04-fold higher risk of death (OR = 16.04; 95% CI, 1.14 to 224.95; P = 0.0395) after adjustment 
for potential confounders. Notably, the fully adjusted OR for mortality was 1.10 in males for each unit 
increase of NLR (OR = 1.10; 95% CI, 1.02 to 1.19; P = 0.016). 
 
Conclusions: NLR is an independent risk factor of the in-hospital mortality for COVID-19 patients 
especially for male. Assessment of NLR may help identify high risk individuals with COVID-19. 
 




The novel coronavirus, named as SARS-CoV-2, was first recognized in Wuhan, China, in December 
2019. Considering the rapid outbreak in China and fast worldwide spread of the coronavirus disease 
2019 (COVID-19) caused by SARS-CoV-2, this infectious disease has aroused emerging global 
concerns. As of March 29, 2020, 82419 people have been diagnosed as COVID-19 in China, among 
them 3306 ended up with death. Moreover, 582131 people worldwide were infected, and the mortality 
rate was 4.7%. As there are currently no standardized treatments and medications available, it is 
crucial to identify risk factors of severe prognosis for COVID-19 patients. 
 
The neutrophil to lymphocyte ratio (NLR), easily calculated from a routinely blood test by dividing 
absolute neutrophil count by absolute lymphocyte count, has been reported of having great value in 
indicating a patient's overall inflammatory status1. Increasing NLR is a risk factor of mortality not only 
in infectious diseases but also in malignancy, acute coronary syndrome, intracerebral hemorrhage, 
polymyositis and dermatomyostis2, 3, 4, 5. A recent research has exhibited that severe cases of COVID-
19 tended to have higher NLR6. Whether NLR could be an independent predictor of mortality in 
hospitalized COVID-19 patients needs to be further elucidated. 
 
So far researches of COVID-19 are focused on the epidemiology and clinical features of the patients7, 8, 
9, information regarding risk factors of mortality is scarce. In the present study, we aim to investigate 




Study design and participants 
For this retrospective cohort study, COVID-19 patients who were admitted to Zhongnan Hospital of 
Wuhan University from January 1 to February 29, 2020 were consecutively included. The clinical 
outcomes, discharge from hospital or death, were recorded up to February 29, 2020. Zhongnan 
Hospital of Wuhan University, located in Wuhan, Hubei Province, is one of the major hospitals 
responsible for the COVID-19 treatment assigned by the government. The diagnosis of COVID-19 
was based on the World Health Organization interim guidance10. The clinical data of 270 patients have 
been obtained, and a flow diagram is showed in Fig. 1. Patients whose age were under 18 years old, 
being pregnant, died on admission, having missing baseline data or being transferred to other 
designated hospitals during hospitalization were excluded. Therefore, 245 patients were included in 
the final analyses. 
 
This study was approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan 
University (Approval Number 2020054) and complied with the Declaration of Helsinki. The data used 
in the study were anonymous, so the requirement for informed consent was waived. 
 
Data collection 
Information included demographic data, comorbidities, symptoms and signs, laboratory findings and 
chest computed tomographic (CT) scans were reviewed. All data were collected with a customized 
form from the electronic hospital information system. The medical records of the patients were 
reviewed by three investigators (JC, XD and YJ) independently to verify data accuracy. 
 
Peripheral venous blood samples were assessed at the central laboratory of Zhongnan hospital 
following standard operative procedures. The routine blood tests (including white blood cell count 
[WBC], leukocyte subtypes, hemoglobin count and platelet count) were measured with XN-9000 
multi-function automatic blood analyzer of fluid (Sysmex Corporation, Kobe, Japan). The 
ARCHITCT ci16200 automatic biochemistry analyzer (Abbott Laboratories, Illinois, United States) 
was used to measure the biochemical parameters. Blood coagulation tests including plasma D-dimer, 
prothrombin time (PT), international normalized ratio (INR), activated partial prothrombin time 
(APTT), thrombin time (TT) were measured by ACL TOP 700 system (Instrumentation Laboratory, 
Milan, Italy). 
 
Identifying of SARS-CoV-2: the throat swab samples were tested for SARS-CoV-2 with the Chinese 
Center for Disease Control and Prevention (CDC) recommended Kit (BioGerm, Shanghai, China) 
following WHO guidelines for qRT-PCR11,12. 
 
Statistical analysis 
Summary statistics of the demographic and clinical characteristics of all patients stratified by NLR 
tertiles were expressed as frequencies and proportions for categorical variables, mean ± SD or median 
and interquartile for continuous variables. The differences among groups were assessed using the chi-
squared test for categorical variables, the one-way ANOVA for normally distributed continuous 
variables, and the Kruskal-Wallis test for skewed continuous variables. 
 
We first examined the relationship of the NLR as a continuous variable with the outcome of in-
hospital death, and then we evaluated this relationship when NLR was treated as variable categorized 
into tertiles. Univariate and multivariate logistic regression models were used to evaluate these 
relationships, then unadjusted and adjusted odds ratio (ORs) and 95% confidence intervals (CIs) were 
calculated. In the multivariate adjusted models, age, gender, body mass index (BMI), hypertension, 
chronic liver diseases, HIV infection, chronic obstructive pulmonary disease (COPD), smoking status 
(never smoked and smokers), respiratory rate (< 30 and ≥ 30 bpm), creatinine, Alanine 
aminotransferase, PT and d-dimer were included. These adjusted features included the ones that, when 
added to this model, changed the odds ratio by at least 10 percent. The lowest tertile was the reference 
for NLR. 
 
Interaction and stratified analyses were conducted according to gender, age (< 60 and ≥ 60 years), 
BMI (< 25 and ≥ 25 kg/m2) and hypertension at baseline. To evaluate the relationships between 
different blood cell types in the blood routine test and the in-hospital death, we repeated the 
multivariate logistic regression models using continuous forms of the blood cell counts. All P values 
were calculated using two-tailed tests of statistical significance with a type I error rate of 5%. All 
statistical analyses were performed using Empower(R) (www.empowerstats.com, X&Y solutions, Inc., 




Of 245 patients included in the final analyses, the mean (standard deviation) age of the cohort was 
53.95 (16.90) years, and 46.53% of the participants were male. The overall number of in-hospital 
death was 33 (13.47%). Table 1 compared the baseline demographic, clinical, and biochemical 
characteristics of included patients by tertiles of the NLR. Compared with subjects in the lowest tertile 
of the NLR, those in the highest tertile were older, more likely to be male. The most common 
symptoms on admission of patients in the highest tertile were fever and dry cough, followed by fatigue 
and poor appetite. Moreover, individuals in the highest tertile were more likely to have underlying 
comorbidities, including hypertension, diabetes, coronary heart disease, chronic liver disease and 
carcinoma. The incidence of in-hospital death significantly increased across NLR tertiles (2.44% vs. 
6.17% vs. 31.71% for tertile 1 vs. tertile 2 vs. tertile 3, respectively). 
 
Table 2 showed the univariate logistic regression models between baseline variables and death. The 
univariate analysis indicated that age (OR = 1.09, 95% CI, 1.06-1.13, P < 0.0001), BMI (OR = 1.15, 
95% CI, 1.01-1.30, P = 0.0328), Hypertension (OR = 3.94, 95%CI, 1.82-8.53, P = 0.0005), Diabetes 
(OR = 3.30, 95% CI, 1.24-8.77, P = 0.0168), CHD (OR = 6.46, 95% CI, 2.33-17.90, P = 0.0003), 
Respiratory rate ≥ 30 bpm (OR = 7.43, 95% CI, 1.76- 31.38, P = 0.0064), Neutrophil (OR = 1.34, 95% 
CI, 1.19-1.50, P < 0.0001), ALT (OR = 1.01, 95% CI, 1.00-1.02, P = 0.0094), Creatinine (OR = 1.01, 
95% CI, 1.00-1.01, P = 0.0177), PT (OR = 1.30, 95% CI, 1.01-1.67, P = 0.0448), C-reactive protein 
and Procalcitonin values were positively correlated with the risk of in-hospital death. The female 
(OR = 0.23, 95% CI, 0.10-0.54, P = 0.0007) and MAP (OR = 0.96, 95% CI, 0.92-0.99, P = 0.0245) was 
negatively correlated with the risk of death. 
 
The results of univariate and multivariate logistic regression models assessing the relations of NLR 
and in-hospital mortality were shown in Table 3. In the unadjusted model, the ORs of death 
significantly augmented as the NLR increased and the tertiles of NLR upgraded. There was a 10% 
increase in risk of in-hospital mortality for per unit increase in NLR (OR = 1.10; 95% CI, 1.05 to 1.14; 
P < 0.0001). The OR for tertile 3 was significantly higher than the OR for tertile 1 (OR = 18.57; 95% 
CI, 4.24 to 81.44; P = 0.0001). Adjustment for demographic variables and comorbidities did not 
weaken the associations between the NLR and death. Further adjusting for the baseline levels of 
respiratory rate, alanine transaminase, creatinine, prothrombin time and D-dimer did not affect the 
relationships in the fully adjusted models. NLR as a continuous variable was associated with 8% 
increased risk of mortality in the fully adjusted models (OR = 1.08; 95%CI, 1.01 to 1.14; P = 0.0147). 
Meanwhile, elevated tertile of NLR exhibited an increase in risk of mortality for the third tertile (vs 
the first tertile) with OR of 16.04 (95% CI, 1.14 to 224.95; P = 0.0395). 
 
To evaluate the consistency of the relationship between NLR and risk of all-cause mortality during 
hospitalization, stratified analyses were performed (Fig. 2). For each unit increase of NLR, the 
adjusted OR for mortality was 1.10 in males (P = 0.016) and 1.00 in females (P = 0.972), and the 
difference for interaction was not statistically significant (P interaction = 0.240). There was a 
borderline significant association for mortality risk in patients less than 60 years (adjusted OR = 1.09; 
95% CI, 1.00 to 1.19; P = 0.053) in comparison with patients 60 years or older (P interaction = 0.786). 
The adjusted OR for patients with normal body mass index (defined as BMI < 25 kg/m2) was 1.06 
(P = 0.107), while in those with an elevated BMI the OR was 1.11 (P = 0.091). The difference of 
interaction was not significant between two groups (P interaction = 0.473). Moreover, increasing NLR 
still was a risk factor for death in patients with or without hypertension, and no evidence of interaction 
effect was found between groups (P interaction = 0.604). 
 
The associations between different blood cell counts and in-hospital mortality were measured and 
shown in Table 4. The risk for mortality increased as the level of baseline neutrophil elevated in the 
adjusted model (OR = 1.30; 95% CI, 1.05 to 1.60; P = 0.0139 in model 2). There was a significant 
association between baseline monocyte count and mortality in the unadjusted model (OR = 6.92; 95% 
CI, 2.01 to 23.84; P = 0.0022), however, the significance faded when considering the cofounders in the 
adjusted models. Additionally, baseline lymphocyte, red blood cells and platelet counts were not 




This retrospective cohort study included 245 COVID-19 patients, and the total in-hospital mortality 
was 13.47%. We found that higher NLR significantly associated with an increased risk of all-cause 
death during hospitalization. Older age and high level of D-dimer are considered independent 
predictors of in-hospital death13. We adjusted age, D-dimer concentrations and other covariates to 
minimize the potential impact of confounding. Moreover, features that, when added to the model, 
changed the odds ratio by at least 10 percent have been added to the multiple logistic regression 
models. Compared with crude regression analyses, this association still persisted when adjusting for 
demographic and clinical variables in the multivariable regression analyses. According to the stratified 
analysis, the risk of mortality tended to be higher as NLR increased in male patients. 
 
Several studies have addressed the difference of baseline leukocyte counts between the clinical stages 
in COVID-19 patients. Qin C et al6. reported that severe cases of COVID-19 were likely to have 
higher neutrophil count but lower lymphocyte count compared with non-severe patients, thus the NLR 
tended to be higher in severe infection patients. Mo P et al14. investigated 155 patients with COVID-19 
and found that refractory patients had higher level of neutrophils in comparison with general patients. 
Moreover, some researchers evaluated the clinical characteristics of the SARS-CoV-2 reactivation. 
The study included 5 reactivated patients, among which one patient had progressive lymphopenia and 
progressive neutrophilia indicating the potential value of leukocyte counts on COVID-19 
reactivation15. Limited by the number of patients, difference of clinical outcome and lack of follow-up, 
the specific risk factors for in-hospital mortality remain to be identified. 
 
In this study, we found that patients with increased NLR had a higher risk for mortality during 
hospitalization after adjustment for other cofounders, meanwhile, the male had a more significant 
association with the risk of mortality than the female. This finding is consistent with the results 
concluded by Mo P et al14. that male patients have a higher incidence of disease refractoriness. Further 
research should be conducted to confirm this result and determine the differences in the 
pathophysiological mechanisms between male and female with COVID-19. 
 
NLR has taken both the levels of neutrophils and lymphocytes into account, and been proposed as a 
new biomarker for systemic inflammation. The high NLR results from increased neutrophil count and 
decreased lymphocyte count. The inflammatory response could stimulate the production of neutrophils 
and speed up the apoptosis of lymphocytes. Dysregulated immune cell responses and consequently 
immunologic abnormality are believed to play remarkable roles in the severity of virus-induced 
disease16. When immune response is dysregulated, it would result in an excessive inflammation, even 
death. One of the most prominent factors associating with the severity and outcomes of the Middle 
East respiratory syndrome coronavirus (MERS-CoV) disease is the hematological change in leukocyte 
populations17. leukocytosis characterized by increased neutrophils and monocytes was primarily 
observed in several MERS-CoV patients, and all the deceased patients showed rapid drops of 
lymphocyte counts18,19. Recent studies showed that higher levels of inflammatory cytokines, 
chemokines and NLR in infected patients were correlated with the severity of the disease than did 
those non-severe patients, suggesting the involvement of cytokine storm in disease severity6,20. These 
findings are consistent with our results. Furthermore, patients with severe virus infection are more 
likely to co-infected with bacteria due to low immune functions, which would be another possible 
reason to explain the increased level of neutrophils, C-reactive protein and procalcitonin shown in our 
study. 
 
The results of this study have several clinical implications and strengths. Since NLR could be quickly 
calculated based on a blood routine test on admission, clinicians may identify high risk COVID-19 
patients at an early stage. Thus, treatments can be modified accordingly to reduce the in-hospital death. 
As this is an observational study and susceptible to various confounders. We adopted strict methods of 
statistical adjustment to minimize potential confounding. In addition, we tested the robustness of the 
results by repeating the analyses with tertiles of the NLR and in different subgroups of gender, age, 
body mass index and history of hypertension. 
 
There are some limitations that should be noted meanwhile. First, the number of observed events is to 
some extent small which limits the statistical power of this explorative study. However, the sample 
size of this research is sufficient to draw a conclusion. Statistical analyses with tertiles of the NLR and 
in subgroups have ensured the reliability of the results. Second, since all subjects in our study were 
hospitalized Chinese patients diagnosed with COVID-19, results of this study might not directly be 
applied to other ethnicities. Third, although we have adjusted for multiple potential confounders, 
residual and unmeasured confounding might not be fully considered. 
 
In conclusion, this retrospective cohort study performed in the Chinese population revealed that the 
NLR is an independent risk factor for the in-hospital mortality. Further researches are needed to 
confirm our findings in other cohorts and to compare the predictive ability of baseline NLR and the 
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Table 1. Baseline characteristics of COVID-19 patients and all-cause death during hospital 
according to the tertiles of neutrophil-lymphocyte ratio (NLR) (n = 245) 
 
Variable Tertile 1 Tertile 2 Tertile 3 P value 
 (0.54-2.21; n=82) (2.21-4.82; n=81) (4.85-88.09; n=82)  
Demographic     
Age, years 47.74 ± 15.83 52.68 ± 17.07 61.41 ± 15.01 <0.001 
Sex    <0.001 
Male 24 (29.27%) 40 (49.38%) 50 (60.98%)  
Female 58 (70.73%) 41 (50.62%) 32 (39.02%)  
BMI (kg/m2) 22.66 ± 2.93 24.41 ± 3.23 23.99 ± 3.65 0.003 
Smoking 1 (1.22%) 4 (4.94%) 5 (6.10%) 0.257 
Symptoms and signs     
Fever 61 (74.39%) 62 (76.54%) 75 (91.46%) 0.010 
Dry cough 39 (47.56%) 49 (60.49%) 52 (63.41%) 0.092 
Fatigue 36 (43.90%) 36 (44.44%) 45 (54.88%) 0.285 
Anorexia 14 (17.07%) 15 (18.52%) 27 (32.93%) 0.028 
Myalgia 24 (29.27%) 27 (33.33%) 24 (29.27%) 0.810 
Dyspnea 8 (9.76%) 10 (12.35%) 27 (32.93%) <0.001 
Sputum 15 (18.29%) 24 (29.63%) 28 (34.15%) 0.064 
Pharyngalgia 9 (10.98%) 7 (8.64%) 1 (1.22%) 0.026 
Diarrhea 6 (7.32%) 8 (9.88%) 4 (4.88%) 0.438 
Nausea 3 (3.66%) 8 (9.88%) 6 (7.32%) 0.278 
Dizziness 3 (3.66%) 2 (2.47%) 5 (6.10%) 0.490 
Headache 5 (6.10%) 5 (6.17%) 2 (2.44%) 0.449 
Vomiting 2 (2.44%) 5 (6.17%) 3 (3.66%) 0.440 
Abdominal pain 3 (3.66%) 0 (0.00%) 0 (0.00%) 0.049 
Respiratory rate > 30 bpm 0 (0.00%) 0 (0.00%) 8 (9.88%) <0.001 
Heart rate, beats per min 81.23 ± 12.01 87.14 ± 13.23 91.40 ± 18.49 <0.001 
MAP, mmHg 88.48 ± 7.87 93.78 ± 10.77 90.34 ± 10.34 0.002 
Comorbidities     
COPD 2 (2.44%) 4 (4.94%) 2 (2.44%) 0.585 
Hypertension 11 (13.41%) 14 (17.28%) 27 (32.93%) 0.005 
Diabetes 5 (6.10%) 6 (7.41%) 12 (14.63%) 0.131 
CHD 5 (6.10%) 3 (3.70%) 10 (12.20%) 0.100 
Carcinoma 2 (2.44%) 1 (1.23%) 6 (7.32%) 0.091 
CLD 0 (0.00%) 3 (3.70%) 4 (4.88%) 0.135 
HIV infection 1 (1.22%) 0 (0.00%) 1 (1.22%) 0.608 
Laboratory findings     
White blood cells, 10^9/L 3.86 ± 1.58 4.23 ± 1.36 8.49 ± 5.69 <0.001 
Neutrophil, 10^9/L 2.03 ± 0.90 2.83 ± 1.00 7.38 ± 5.37 <0.001 
Lymphocyte, 10^9/L 1.39 ± 0.67 0.92 ± 0.31 0.62 ± 0.35 <0.001 
Red blood cells, 10^12/L 4.09 ± 0.52 4.22 ± 0.56 4.04 ± 0.79 0.161 
Hemoglobin, G/L 127.89 ± 15.59 130.39 ± 13.73 124.33 ± 24.79 0.117 
Platelet, 10^9/L 178.39 ± 47.57 174.70 ± 66.60 191.49 ± 89.23 0.274 
ALT, U/L 23.93 ± 18.08 26.77 ± 17.79 40.56 ± 42.19 <0.001 
AST, U/L 27.65 ± 12.91 36.16 ± 27.33 52.10 ± 57.68 <0.001 
Glucose, mmol/L 5.84 ± 1.47 6.81 ± 3.30 8.22 ± 3.85 <0.001 
Blood urea nitrogen, 
mmol/L 
4.20 ± 1.60 4.69 ± 2.34 8.06 ± 8.31 <0.001 
Creatinine, µmol/L 65.60 ± 20.48 75.06 ± 37.49 118.18 ± 180.33 <0.001 
D-dimer, ng/mL 303.63 ± 565.30 685.37 ± 3143.50 2287.51 ± 6052.35 <0.001 
PT, sec 12.39 ± 0.90 12.81 ± 1.01 13.42 ± 1.73 <0.001 
APTT, % 31.03 ± 2.32 31.33 ± 3.82 31.27 ± 5.35 0.410 
TT, sec 14.82 ± 1.91 14.98 ± 1.49 15.55 ± 4.01 0.198 
C-reactive protein, mg/L 14.18 ± 16.58 36.18 ± 36.18 94.63 ± 76.13 <0.001 
Procalcitonin, ng/mL    <0.001 
<0.1 72 (93.51%) 69 (90.79%) 38 (46.34%)  
> 0.1, <0.5 5 (6.49%) 4 (5.26%) 26 (31.71%)  
> 0.5, <1 0 (0.00%) 3 (3.95%) 7 (8.54%)  
> 1 0 (0.00%) 0 (0.00%) 11 (13.41%)  
Imaging features     
Consolidation or Ground-
glass opacity 
77 (95.06%) 78 (97.50%) 82 (100.00%) 0.108 
All-cause death 2 (2.44%) 5 (6.17%) 26 (31.71%) <0.001 
	
Data are mean ± SD, median (interquartile range), or percentage. P values comparing groups are from 
a χ² test for categorical variables, and ANOVA for continuous variables. BMI = Body mass index. 
MAP = mean arterial pressure. COPD = chronic obstructive pulmonary disease. CHD = coronary heart 
disease; CLD = chronic liver disease. ALT = alanine transaminase. AST = aspartate transaminase. 
PT = prothrombin time. APTT = activated partial thromboplastin time. TT = thrombin time. 
Table 2. The unadjusted association between baseline variables and all-cause death during 
hospitalization (n = 245) 
	
Variable Statistics Odds ratio (95% CIs) P value 
Age, years 53.95 ± 16.90 1.09 (1.06, 1.13) <0.0001 
Sex    
Male 114 (46.53%) 1.0  
Female 131 (53.47%) 0.23 (0.10, 0.54) 0.0007 
BMI (kg/m2) 23.67 ± 3.34 1.15 (1.01, 1.30) 0.0328 
COPD    
No 237 (96.73%) 1.0  
Yes 8 (3.27%) 4.14 (0.94, 18.22) 0.0602 
Hypertension    
No 193 (78.78%) 1.0  
Yes 52 (21.22%) 3.94 (1.82, 8.53) 0.0005 
Diabetes    
No 222 (90.61%) 1.0  
Yes 23 (9.39%) 3.30 (1.24, 8.77) 0.0168 
CHD    
No 227 (92.65%) 1.0  
Yes 18 (7.35%) 6.46 (2.33, 17.90) 0.0003 
Carcinoma    
No 236 (96.33%) 1.0  
Yes 9 (3.67%) 1.89 (0.38, 9.51) 0.4404 
CLD    
No 238 (97.14%) 1.0  
Yes 7 (2.86%) 2.67 (0.50, 14.37) 0.2525 
HIV infection    
No 243 (99.18%) 1.0  
Yes 2 (0.82%) -* 0.9894 
Smoking    
No 235 (95.92%) 1.0  
Yes 10 (4.08%) 2.93 (0.72, 11.94) 0.1341 
Heart rate, bpm 86.59 ± 15.37 1.01 (0.99, 1.03) 0.3044 
MAP, mmHg 90.86 ± 9.94 0.96 (0.92, 0.99) 0.0245 
Respiratory rate, bpm    
< 30 236 (96.72%) 1.0  
> 30 8 (3.28%) 7.43 (1.76, 31.38) 0.0064 
Neutrophil, 10^9/L 4.09 ± 3.97 1.34 (1.19, 1.50) <0.0001 
Lymphocyte, 10^9/L 0.98 ± 0.57 0.58 (0.26, 1.32) 0.1979 
Hemoglobin, G/L 127.52 ± 18.78 0.98 (0.96, 1.00) 0.0504 
Platelet, 10^9/L 181.56 ± 70.01 0.99 (0.99, 1.00) 0.0507 
ALT, U/L 30.48 ± 29.33 1.01 (1.00, 1.02) 0.0094 
Creatinine, µmol/L 86.46 ± 109.60 1.01 (1.00, 1.01) 0.0177 
PT, sec 12.88 ± 1.34 1.30 (1.01, 1.67) 0.0448 
D-dimer, ng/mL 1102.17 ± 4050.14 1.00 (1.00, 1.00) 0.1123 
C-reactive protein, mg/L 45.77 ± 57.85 1.02 (1.01, 1.03) <0.0001 
Procalcitonin, ng/mL    
<0.1 179 (76.17%) 1.0  
> 0.1, <0.5 35 (14.89%) 66.37 (14.14, 311.53) <0.0001 
> 0.5, <1 10 (4.26%) 206.50 (29.61, 1440.03) <0.0001 
> 1 11 (4.68%) 398.25 (50.19, 3160.05) <0.0001 
 
Data are mean ± SD, n (%), n/N (%), or median (IQR). 
BMI = Body mass index. COPD = chronic obstructive pulmonary disease. CHD = coronary heart 
disease; CLD = chronic liver disease. MAP = mean arterial pressure. ALT = alanine transaminase. 
PT = prothrombin time. 
⁎The model failed because of the small sample size. 
Table 3. Risk association between baseline NLR and in-hospital death 
 
 Unadjusted Odds 
ratio 
(95% CIs) 
P value Model 1a 
Odds ratio (95% 
CIs) 
P value Model 2b 
Odds ratio (95% 
CIs) 
P value 
NLR 1.10 (1.05, 1.14) <0.0001 1.09 (1.03, 1.14) 0.0013 1.08 (1.01, 1.14) 0.0147 
Tertiles 
NLR 
      
Tertile 1 1.0  1.0  1.0  
Tertile 2 2.63 (0.50, 13.97) 0.2560 1.71 (0.14, 21.38) 0.6768 1.52 (0.09, 25.08) 0.7700 
Tertile 3 18.57 (4.24, 81.44) 0.0001 16.61 (1.58, 
174.66) 




a Model 1 was adjusted for age, sex, body mass index, history of Hypertension, history of chronic liver 
disease, history of HIV infection, history of chronic obstructive pulmonary disease, smoking status. 
 
b Model 2 was adjusted for age, sex, body mass index, history of Hypertension, history of chronic liver 
disease, history of HIV infection, history of chronic obstructive pulmonary disease, smoking status, 
respiratory rate, alanine transaminase, creatinine, prothrombin time, D-dimer. 
 






P value Model 1a 
Odds ratio (95% 
CIs) 
P value Model 2b 





1.34 (1.19, 1.50) <0.0001 1.26 (1.08, 1.47) 0.0030 1.30 (1.05, 1.60) 0.0139 
Lymphocyte, 
10^9/L 
0.58 (0.26, 1.32) 0.1979 0.81 (0.37, 1.78) 0.6009 0.86 (0.34, 2.15) 0.7431 
Monocyte, 
10^9/L 
6.92 (2.01, 23.84) 0.0022 2.55 (0.47, 13.80) 0.2788 0.78 (0.04, 13.47) 0.8617 
Red blood cells, 
10^12/L 
0.60 (0.34, 1.06) 0.0800 0.84 (0.28, 2.50) 0.7553 0.48 (0.14, 1.70) 0.2576 
Platelet, 10^9/L 0.99 (0.99, 1.00) 0.0507 0.99 (0.98, 1.00) 0.0428 0.99 (0.98, 1.00) 0.1609 
 
a Model 1 was adjusted for age, sex, body mass index, history of Hypertension, history of chronic liver 
disease, history of HIV infection, history of chronic obstructive pulmonary disease, smoking status. 
 
b Model 2 was adjusted for age, sex, body mass index, history of Hypertension, history of chronic liver 
disease, history of HIV infection, history of chronic obstructive pulmonary disease, smoking status, 
respiratory rate, alanine transaminase, creatinine, prothrombin time, D-dimer. 
 





Fig. 2. Risk associations between NLR as a continuous variable and in-hospital death in 
subgroups of gender, age, body mass index and history of hypertension 
 
Data were adjusted for age, sex, body mass index, history of Hypertension, history of chronic liver 
disease, history of HIV infection, history of chronic obstructive pulmonary disease, smoking status, 
respiratory rate, alanine transaminase, creatinine, prothrombin time, D-dimer. 
 
